Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease

Abstract Objectives Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocomp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Andrea S Henden, Katie E Lineburg, Archana Panikkar, Arushi Mahajan, Ricky Nelles, Emma Wright, Pauline Crooks, Jyothy Raju, Laetitia Le Texier, Srividhya Swaminathan, Leone Beagley, Shannon Best, Matthew Solomon, Hilary Reddiex, Glen Kennedy, Siok‐Keen Tey, Michelle A Neller, Rajiv Khanna, Corey Smith
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-01-01
Serie:	Clinical & Translational Immunology
Soggetti:	COVID‐19 immunocompromised SARS‐CoV‐2 VST therapy
Accesso online:	https://doi.org/10.1002/cti2.70038
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!